MGNX earnings analysis
What we found in MGNX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
MacroGenics reported $32.8 million of second-quarter revenue, up 375% year over year, but the increase was primarily milestone-driven by a $24.5 million TZIELD payment and higher ZYNYZ royalties. Diluted EPS was -$0.27, although R&D and G&A expenses declined to $38.8 million and $7.9 million, respectively. The $119.6 million Bora proceeds and additional expected partner payments extend the stated cash runway through 2028, but the company now faces heightened outsourced-manufacturing and CRO execution risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Milestone drove sharp revenue growth
- Revenue was $32.8 million, up $25.9 million, or 375%, versus $6.9 million in the prior-year quarter. The increase was driven primarily by a $24.5 million TZIELD regulatory milestone and $6.0 million of additional ZYNYZ royalty revenue.
- ZYNYZ royalties accelerated
- Royalty revenue increased to $7.3 million from $1.3 million, up 462% year over year, reflecting higher ZYNYZ sales.
- Operating expenses decreased
- Research and development expense declined 5% to $38.8 million from $40.8 million year over year, while general and administrative expense fell to $7.9 million from $9.3 million.
- CDMO divestiture strengthened liquidity
- The Bora transaction generated a pretax net gain of $86.1 million from the sale of the CDMO Operations. Bora paid $119.6 million net of customary adjustments in July 2026 and assumed responsibility for the operations.
- Cash burn improved year over year
- Six-month operating cash use improved to $76.6 million from $93.9 million in the prior-year period. Investing activities provided $73.3 million versus using $27.7 million a year earlier, while financing activities provided $60.0 million.
- Lead pipeline programs received funding
- Clinical investment shifted toward MGC028 and MGC026, with quarterly R&D spending of $10.2 million and $7.2 million, respectively, up 117% and 140% year over year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Reliance on outsourced manufacturing
- Following the June 30, 2026 sale, MacroGenics no longer operates its own GMP facility and must rely on third parties, including Bora, for clinical and potential commercial manufacturing. Bora paid $119.6 million net of adjustments, but capacity, quality or regulatory failures could delay trials or commercialization.
- Post-sale liabilities and indemnities
- The company may retain liabilities related to the divested CDMO business, including employee, tax, environmental, product-quality and regulatory matters, and may have indemnification obligations to Bora. The transaction had a stated purchase price of $122.5 million before closing adjustments.
- CRO transition could delay trials
- MacroGenics is transitioning more clinical and development work to CROs and warns that switching providers can cause delays. The company spent $38.8 million on R&D in the quarter, including $10.2 million on MGC028 and $7.2 million on MGC026, increasing the potential impact of execution delays.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
- Segment
- Collaborative and other agreements: $25.5 million, up $19.9 million or 355% year over year
- Segment
- Royalty revenue: $7.3 million, up $6.0 million or 462% year over year
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management said cash, cash equivalents and marketable securities at June 30, 2026, plus $119.6 million received from Bora, a $24.5 million Sanofi milestone due in September 2026, a $10.0 million Gilead payment and expected partner payments and cost savings support a cash runway through 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- MacroGenics, Inc. reported revenue of $20.8 million for the first quarter of 2026, marking a 58% increase from $13.2 million in the same period last year, driven by significant growth in contract manufacturing and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MGNX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever